Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 537-542

  Penel, N ^a   Demetri, G D ^b   Blay, J Y ^c   Cousin, S ^a   Maki, R G ^d   Chawla, S P ^e   Judson, I ^f   von Mehren, M ^g   Schoffski P ^h   Verweij, J ⁱ   Casali, P ^j   Rodenhuis, S ^k   Schutte H J ^l   Cassar, A ^m   Gomez, J ⁿ   Nieto, A ⁿ   Zintl, P ⁿ   Pontes, M J ⁿ   Le Cesne, A ^o  

^a CENTRE OSCAR LAMBRET   (France)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c CENTRE LÉON BÉRARD   (France)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Medical Oncology Department   (United States)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g Medical Oncology Department   (United Kingdom)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k NETHERLANDS CANCER INSTITUTE   (Netherlands)

^l MARIEN HOSPITAL DÜSSELDORF   (Germany)

^m Scientific liaison office   (France)

ⁿ Statistics Department and Medical affairs   (Spain)

^o INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Growth modulation index; Sarcoma; Time to progression ratio; Trabectedin

Indexed keywords

TRABECTEDIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GROWTH MODULATION INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SECONDARY HEALTH CARE; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL PROLIFERATION; DIOXOLES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SARCOMA; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873733013     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds470     Document Type: Article

References (29)

1. Clark MA, Fisher C, Judson I et al. Soft-tissue sarcomas in adults. N Engl J Med 2005; 353: 701-711.
2. Blay JY, van Glabbeke M, Verweij J et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39: 64-69.
3. Penel N, Van Glabbeke M, Marreaud S et al. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2011; 22: 1266-1272.
4. Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22: 1480-1490.
5. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23: 576-584.
6. Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22: 890-899.
7. Van Glabbeke M, Hogendoorn PCW, Mouridsen H et al. Progression free rate as the principal end-point for phase II trial on soft tissue sarcoma: what should be the target? A retrospective study of the EORTC soft tissue and bone sarcoma (STBSG) database. J Clin Oncol 2001; 20: 354 (abstract 1413).
8. Krasner CN, McMeekin DS, Chan S et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinumbased regimens. Br J Cancer 2007; 17: 1618-1624.
9. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
10. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20: 1794-1802.
11. Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-549.
12. Cousin S, Taieb S, Penel N. A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials. Curr Opin Oncol 2012; 24: 338-344.
13. Verweij J. Other endpoints in screening studies for soft tissue sarcomas. Oncologist 2008; 13(Suppl 2): 27-31.
14. Mehrabi A, Kashfi A, Fonouni H et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006; 107: 2108-2121.
15. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26: 5269-5274.
16. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-3132.
17. Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140.
18. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595-602.
19. Italiano A, Toulmonde M, Cioffi A et al Advanced well-differentiated/ dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 2011; 23: 1601-1607.
20. Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998; 4: 1079-1086.
21. Zalcberg JR, Verweij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-1757.
22. Bonetti A, Zaninelli M, Leone R et al. Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma. Ann Oncol 2001; 12: 187-191.
23. Comella P, Casaretti R, Crucitta E et al. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer 2002; 86: 1871-1875.
24. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 2000; 21: 343-359.
25. Kovalchik S, Mietlowski W. Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint. Contemp Clin Trials 2011; 32: 99-107.
26. Penel N, Glabbeke MV, Mathoulin-Pelissier S et al. Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. Br J Cancer 2011; 104: 1544-1550.
27. Von Hoff DD, Stephenson JJ, Jr, Rosen P et al. Pilot study using molecular profiling of patients tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-4883.
28. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103.
29. Germano G, Frapolli R, Simone M et al Antitumor and anti-inflammatory effects of trabectedin on human myxioid liposarcoma cells. Cancer Res 2010; 70: 2235-2244.